Valuation: BICYCL

Market Cap 258M 229M 214M 195M 367M 24.8B 372M 2.59B 1B 12.63B 967M 946M 40.57B P/E 2026 *
-1.41x
P/E 2027 * -1.57x
Enterprise Value -255M -227M -212M -193M -364M -24.57B -369M -2.56B -993M -12.52B -958M -937M -40.2B EV / Sales 2026 *
-14.6x
EV / Sales 2027 * -21.8x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 258M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.04%+1.97%+55.43%+154.28% 44.09B
Weighted average by Cap. +0.18%+1.83%+60.06%+145.78%

Financials

2026 *2027 *
Net sales 17.53M 15.57M 14.56M 13.27M 24.98M 1.69B 25.33M 176M 68.2M 860M 65.83M 64.4M 2.76B 6.69M 5.94M 5.56M 5.06M 9.53M 644M 9.66M 67.21M 26.02M 328M 25.11M 24.57M 1.05B
Net income -172M -153M -143M -130M -245M -16.57B -249M -1.73B -669M -8.44B -646M -632M -27.1B -175M -156M -145M -133M -250M -16.86B -253M -1.76B -681M -8.59B -657M -643M -27.58B
Net Debt -513M -455M -426M -388M -731M -49.37B -741M -5.15B -1.99B -25.15B -1.93B -1.88B -80.76B -403M -358M -335M -305M -575M -38.83B -583M -4.05B -1.57B -19.78B -1.51B -1.48B -63.53B
Logo BICYCL
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-